Ticker

Nutex Health is rated a buy, driven by the potential passage of the No Surprises Enforcement Act. NUTX's $387 million in receivables could rapidly convert to cash if the bill passes, eliminating a key valuation overhang. The company trades at 5.2x P/E despite 49% projected 2026 revenue growth and a 27% TTM operating margin, reflecting market skepticism over payment collections.

HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March…

Principal Financial Group Inc. purchased a new stake in Nutex Health Inc. (NASDAQ: NUTX) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 9,314 shares of the company's stock, valued at approximately $962,000. Principal Financial Group Inc. owned

Medpace (NASDAQ: MEDP - Get Free Report) and Nutex Health (NASDAQ: NUTX - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk. Profitability This table compares Medpace and Nutex Health's net

Exploring the Investment Strategies of John Hussman (Trades, Portfolio) in Q4 2025 John Hussman (Trades, Portfolio) recently submitted the 13F filing for the f